In this webinar, we will explain how IDT's hybridization capture solutions are assisting researchers with overcoming challenges associated with circulating tumor DNA (ctDNA) for minimal residual disease (MRD) research. You will also gain insights about the importance of minimal residual disease research, how it compares to traditional methods, and the impact it is making with the discovery of new biomarkers. We hope by bringing these studies into the spotlight, it will foster new collaborations and discoveries within oncology research.
In this webinar you will learn:
For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Bioinformatician, Geneseeq
Haimeng has a B.S. in Biotechnology from the University of Toronto and obtained his MS from Brock University in 2021. His work focuses on genetic markers for drug resistance, MRD detection, and early detection of cancers.
Manager, Strategic Marketing , Integrated DNA Technologies
Jordan leads IDT's account-based marketing programs and is responsible for establishing new partnerships and collaborations with institutions and researchers around the world. Prior to IDT, he held multiple positions ranging from product management to sales in cell biology, genomics, and medical devices. Jordan has a BS in Applied Biology and an MBS with a focus in life sciences and biotechnology.